Obinutuzumab-Induced Acute Hypophosphatemia in Phospholipase A2 Receptor (PLA2R)-Positive Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0616; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 42-year-old man with biopsy-proven PLA2R-positive MN previously treated with rituximab without achieving partial or complete remission and was maintained on cyclosporine due to financial reasons...Initial labs: creatinine: 2.9 mg/dl (baseline creatinine of ~1.7 mg/dL), 24-hour urine protein: 6.9 gms, sodium: 135 meq/l, potassium: 4.4 meq/l, bicarbonate: 18 meq/l, corrected calcium: 9.5 meq/l, phosphorus: 4.3 meq/l, serum albumin: 2.4 gm/dl, Anti-PLA2R Antibody titer: 8, and lisinopril and cyclosporine were held...To our knowledge, this is the first reported case of isolated severe hypophosphatemia following obinutuzumab in PLA2R-positive MN. Clinicians should consider monitoring serum phosphate after obinutuzumab infusion in high-risk patients."
Chronic Kidney Disease • Glomerulonephritis • Metabolic Disorders • Nephrology • Renal Disease
|
|
Krishna Vani Nemalidinne; Abinay Siva kumar Reddy Vanteru; Husam Mohammad Alzghoul; Saad Abdulrahim Talal Mahmoud; Nadia Mustafa Alqurini
|